ViroPharma Incorporated Reports Second Quarter 2009 Financi... (i There can be no ass...)

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

Date:7/29/2009

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. There can be no assurance that we will conduct additional studies with for acute treatment of HAE or that we will be successful in gaining regulatory approval of Cinryze for additional indications, formulations or in additional territories. In addition, approval of a competing product which has been granted orphan drug designation would prevent Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2008 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

                              VIROPHARMA INCORPORATED
                       Selected Financial Information- GAAP

    Consolidated Statements of Operations:
    (in thousands, except per           Three months ended   Six months ended
     share 
'/>"/>
SOURCE  ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved 
0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema

Post Your Comments:

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...

(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...

(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...

(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...

(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...

Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2 Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3 Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3 Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2

[0] New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations [0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics [0] Long-term study reports deep brain stimulation effective for most common hereditary dystonia [0] States vary widely on success rates for minorities in drug treatment programs [0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center

... healthcare,provider and supplier organizations with its GHXcellence Awards for,achievements ... Friday, April 18, 2008 during a recognition ceremony in,Chicago ... largest healthcare,forum in the U.S. focused on both the ... theme of this year,s awards was improved utilization of ...

... Once locked in decades of isolation, Albania is seeing new ... demands for better and healthier lives. , People ... Institute of Public Health and Hygiene. They want better, more ... keep pace with those expectations, but there are problems. , ...

... Fla., April 23 LifeSync Corporation, a,wholly ... it has entered,into a non-exclusive sublicense with ... with the digital, wireless communication of,patient vital ... Wireless the right to utilize,LifeSync,s technologies in ...

... The Beryl Companies, the nation,s,leading healthcare call ... of operations. In this role she will oversee ... recruitment and,training of managerial staff. Butterfield brings nearly ... vendor management., "Lindy is a highly regarded ...

... for cancer patients , , WEDNESDAY, April 23 (HealthDay News) ... developing a simple way to measure oxygen levels in ... treatment is best for individual patients. , The ... for patients with cancer instead of treating people the ...

... quarter of ... per share, including net realized investment losses ... cash flow was $1.0 billion, or approximately 1.8 times net ... income, -- Full year 2008 net income is now expected to be in the range of $5.42 -, ...

GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance Albania: Rising expectations drive growing health care needs LifeSync Corporation Agrees to Sublicense Patent Portfolio to Triage Wireless New VP of Operations Enhances The Beryl Companies' Leadership Team Scan Detects Oxygen Levels in Tumors WellPoint Reports First Quarter 2008 Results

(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...

(Date:6/19/2013)... -- Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...

(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...

[0] Drug Patent Watch [0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research

... , MINNEAPOLIS, Aug. 11 ProUroCare Medical, Inc. (OTC ... the required three centers in its FDA clinical study of the ... , ProUroCare began the current study with the ... having more than 40 patients enrolled overall. Since beginning, five ...

... Aug. 10 Bionovo, Inc. (Nasdaq: BNVI ) today announced second quarter ... , Company Highlights , , , ... in 27 patients with metastatic breast cancer showed ... evidence of clinical activity, in a heavily pretreated ...

Cached Medicine Technology:ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 2 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 2 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 3 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 5 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 6 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 7 Bionovo Announces Second Quarter 2009 Highlights and Financial Results 8

ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology Bionovo Announces Second Quarter 2009 Highlights and Financial Results

... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...

... a constant voltage power supply, the 105 is ... hilo range switch control the output, which is ... volts. One, two-position switch toggles the bright LED ... The 105 is equipped with an over current ...

... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...

MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...

Medicine Products:

Model 583 Gel Dryer (220-240 V)105 Low Voltage Power Supply High Voltage Programmable Power Supplies Midi Power Supply